07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver disease High mobility group box 1 (HMGB1) Studies in patient samples and mice suggest inhibiting HMGB1 could help treat alcoholic liver disease. In...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Recomodulin: Phase III started

Asahi Kasei began a double-blind, placebo-controlled, international Phase III trial to evaluate 0.06 mg/kg IV ART-123 for up to 6 mg per day for 6 days in about 800 severe sepsis patients with coagulopathy. ART-123...
07:00 , May 31, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host disease (GvHD) Thrombomodulin (THBD; CD141) In vitro and mouse studies suggest vitamin D-treated CD141+ dendritic cells (DCs) could induce immune tolerance and help treat...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Paion cardiovascular, neurology news

Paion issued an update for its ongoing restructuring will now reduce headcount to 11 employees. Late last year, Paion said it would reduce headcount by 19 (70%) to eight to reduce costs and focus on...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Paion cardiovascular, neurology news

Paion also said it has not identified a partner for pain product M6G . The biotech noted its chances of partnering it are "considerably lower than expected in the past" and will result in an...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Company News

Artisan Pharma, Asahi Kasei Pharma deal

Asahi acquired its 2006 spinout Artisan. Asahi said Artisan will become its base for U.S. development of pharmaceuticals. Artisan has rights to Asahi's ART-123 outside of Japan, China, Taiwan and South Korea. The soluble form...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Clinical News

Solulin: Phase Ib started

Paion began an open-label, international Phase Ib trial to evaluate single doses of IV Solulin in patients with severe hemophilia A receiving chronic therapy with coagulation Factor VIII. Paion AG (Xetra:PA8), Aachen, Germany   Product:...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

ART-123: Completed Phase IIb enrollment

Artisan completed enrollment of 750 sepsis patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating 6 mg/mL injectable ART-123. The product is approved for the indication in Japan. Artisan spun out of Asahi in...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Aushon sales and marketing update

Aushon launched its Human Vascular Injury Panels to quantify seven biomarkers related to drug-induced vascular injury, including E selectin ( SELE ; CD62E ); P selectin ( SELP ; CD62P ); intercellular adhesion molecule-3 (...